Richard S Finn

List of Publications by Year
in descending order

81 papers	13,889 citations	136950 32 h-index	76900 74 g-index
83 all docs	83 docs citations	83 times ranked	12914 citing authors

#	Article	IF	Citations
1	Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172.	27.6	643
2	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	10.7	526
3	Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.. Journal of Clinical Oncology, 2022, 40, 433-433.	1.6	6
4	LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2022, 40, TPS494-TPS494.	1.6	2
5	Ramucirumab for patients with advanced hepatocellular carcinoma and elevated Î±-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2.. Journal of Clinical Oncology, 2022, 40, 423-423.	1.6	3
6	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. CardioVascular and Interventional Radiology, 2022, 45, 405-412.	2.0	35
7	Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET. Cancer Research, 2022, 82, PD2-07-PD2-07.	0.9	0
8	Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptorâ€“positive/human epidermal growth factor receptor 2â€“negative advanced breast cancer (ER+/HER2â^' ABC): Analyses from PALOMA-2.. Journal of Clinical Oncology, 2022, 40, LBA1003-LBA1003.	1.6	95
9	Evolution of Systemic Therapy for Hepatocellular Carcinoma. Hepatology, 2021, 73, 150-157.	7.3	70
10	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607.	3.9	13
11	Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. Targeted Oncology, 2021, 16, 69-76.	3.6	19
12	Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 268-268.	1.6	10
13	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 318-318.	1.6	0
14	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer, 2021, 124, 1388-1397.	6.4	39
15	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, e16122-e16122.	1.6	0
16	Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.. Journal of Clinical Oncology, 2021, 39, 4146-4146.	1.6	0
17	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated Î± â€fetoprotein: Outcomes by treatmentâ€emergent ascites. Hepatology Research, 2021, 51, 715-721.	3.4	5
18	Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2021, 39, 4084-4084.	1.6	1

#	Article	IF	Citations
19	Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2021, 39, 4100-4100.	1.6	17
20	Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 4072-4072.	1.6	2
21	Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2021, 39, 4090-4090.	1.6	5
22	Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. Oncologist, 2021, 26, e1143-e1155.	3.7	15
23	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
24	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer, 2021, 10, 451-460.	7.7	5
25	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clinical Breast Cancer, 2020, 20, e173-e180.	2.4	21
26	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative metastatic breast cancer. Breast Journal, 2020, 26, 368-375.	1.0	8
27	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-NaÃ¯ve Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 110-121.	7.0	120
28	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2â¯ advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Research and Treatment, 2020, 183, 419-428.	2.5	73
29	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Research and Treatment, 2020, 184, 23-35.	2.5	21
30	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 2020, 38, 2960-2970.	1.6	723
31	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nature Communications, 2020, 11, 4489.	12.8	134
32	Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells. Npj Precision Oncology, 2020, 4, 16.	5.4	16
33	A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2020, 38, 4519-4519.	1.6	50
34	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. Journal of Clinical Oncology, 2020, 38, 4587-4587.	1.6	2
35	Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study.. Journal of Clinical Oncology, 2020, 38, e16680-e16680.	1.6	5
36	Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial.. Journal of Clinical Oncology, 2020, 38, 542-542.	1.6	4

#	Article	IF	Citations
37	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi Journal of Gastroenterology, 2020, 26, 1.	1.1	13
38	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 419-430.	6.3	55
39	Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, 2019, 121, 218-221.	6.4	22
40	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased Î±-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 282-296.	10.7	1,202
41	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology, 2019, 5, 1-19.	0.5	34
42	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2â^' Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist, 2019, 24, 1514-1525.	3.7	49
43	Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 1731-1741.	1.3	160
44	Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of Î±-fetoprotein. Lancet Oncology, The, 2019, 20, e191.	10.7	42
45	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. Journal of Clinical Oncology, 2019, 37, TPS4152-TPS4152.	1.6	94
46	A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Liver Transplantation, 2018, 24, 946-960.	2.4	58
47	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. Journal of Hepatology, 2018, 69, 353-358.	3.7	270
48	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	10.7	1,816
49	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	7.7	124
50	Molecular therapies and precision medicine for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2018, 15, 599-616.	27.6	1,308
51	Palbociclib plus endocrine therapy in older women with HR+/HER2â€“ advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. European Journal of Cancer, 2018, 101, 123-133.	2.8	59
52	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS4141-TPS4141.	1.6	38
53	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. British Journal of Cancer, 2017, 116, 575-583.	6.4	73
54	Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10â€year intentionâ€toâ€treat analysis. Hepatology, 2017, 65, 1979-1990.	7.3	87

#	Article	IF	Citations
55	Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. Journal of Clinical Pharmacology, 2017, 57, 1159-1173.	2.0	30
56	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 56-66.	13.7	2,771
57	Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. Hepatology, 2017, 66, 1344-1346.	7.3	28
58	Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection. Liver Transplantation, 2017, 23, 1123-1132.	2.4	27
59	Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.. Journal of Clinical Oncology, 2017, 35, 344-344.	1.6	16
60	Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Advances in Radiation Oncology, 2016, 1, 237-243.	1.2	43
61	Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1925-1936.	27.0	1,943
62	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2â€“ advanced breast cancer (ABC).. Journal of Clinical Oncology, 2016, 34, 507-507.	1.6	72
63	Neratinib to inhibit the growth of triple-negative breast cancer cells.. Journal of Clinical Oncology, 2015, 33, 1099-1099.	1.6	7
64	Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).. Journal of Clinical Oncology, 2015, 33, 570-570.	1.6	5
65	Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged â‰¥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.. Journal of Clinical Oncology, 2015, 33, 571-571.	1.6	2
66	The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.. Journal of Clinical Oncology, 2015, 33, 572-572.	1.6	1
67	Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.. Journal of Clinical Oncology, 2015, 33, 575-575.	1.6	6
68	Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer. JAMA Ophthalmology, 2014, 132, 1005.	2.5	74
69	Hepatic Oncology: a journal for all stakeholders in liver cancer management. Hepatic Oncology, 2014, 1, 1-1.	4.2	0
70	DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes and Cancer, 2014, 5, 407-419.	1.9	19
71	Multicenter phase I trial of sorafenib (S) in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation (LT).. Journal of Clinical Oncology, 2014, 32, 285-285.	1.6	0
72	Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, TPS4159-TPS4159.	1.6	6

#	Article	IF	Citations
73	A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(â€“) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.. Journal of Clinical Oncology, 2013, 31, TPS652-TPS652.	1.6	7
74	Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study.. Journal of Clinical Oncology, 2013, 31, 300-300.	1.6	5
75	Phase I trial of sorafenib in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation.. Journal of Clinical Oncology, 2013, 31, 280-280.	1.6	0
76	Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.. Journal of Clinical Oncology, 2013, 31, TPS4163-TPS4163.	1.6	1
77	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer, 2012, 1, 247-256.	7.7	65
78	A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.. Journal of Clinical Oncology, 2012, 30, 220-220.	1.6	27
79	Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S3783.	0.4	13
80	Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene, 1999, 18, 6050-6062.	5.9	131
81	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 1998, 17, 2235-2249.	5.9	353